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Abstract
Aim: To evaluate the current evidence assessing the use of exercise 
prehabilitation interventions during neoadjuvant cancer treatment in those 
patients with gastrointestinal or thoracic cancer.
Methods: A comprehensive and systematic database search was performed 
to identify all published clinical studies involving exercise prehabilitation during 
neoadjuvant cancer treatment for patients diagnosed with gastrointestinal 
or thoracic cancer. Pre-defined criteria were used to identify relevant articles 
and the Modified Downs and Black checklist was used for quality assessment 
purposes.
Results: The search identified 508 relevant abstracts. After screening, 
18 full-text articles were assessed for eligibility and inclusion. Three full-text 
articles met all the search criteria and were included in the review. Physical 
fitness was the main outcome measure and an improvement in physical fitness 
was observed in all three included studies. There was good adherence to the 
exercise programmes with a lack of associated adverse events, suggesting 
safety and feasibility of such interventions in this setting. A differentiation 
between ‘responders’ and ‘non-responders’ to exercise training was identified 
for the first time. 
Conclusions: This is the first systematic review assessing the use of 
exercise prehabilitation during neoadjuvant cancer treatment in patients with 
gastrointestinal and thoracic cancer. Although this review demonstrates the safe 
use of exercise prehabilitation during neoadjuvant cancer treatment in patients 
with gastrointestinal and thoracic cancer, there is still insufficient evidence 
to support any robust conclusions regarding the ideal characteristics of an 
exercise prehabilitation intervention and the impact it may have on clinical and 
post-operative outcomes.
Keywords: Exercise prehabilitation; Oncology; Surgery; Neoadjuvant 
cancer treatment; Gastrointestinal; Thoracic
Introduction
‘Prehabilitation’ is the process of preparing and improving 
functional capacity ahead of a planned physiological stressor [1]. 
Surgical prehabilitation is being used in a variety of settings but is 
novel in the field of neoadjuvant therapy. In patients with upper and 
lower gastrointestinal cancer there is good evidence demonstrating a 
decrease in physical fitness when patients have multi-modality therapy 
(chemotherapy in combination with radiotherapy and surgery) in the 
neoadjuvant setting [2,3]. In addition, those patients who receive 
chemotherapy in combination with radiotherapy and surgery have 
decreased levels of physical fitness when compared to those patients 
who receive radiotherapy or surgery alone [4]. These affects have been 
shown to decrease objectively measured physical fitness, assessed 
using cardiopulmonary exercise testing (CPET), which in turn has 
been associated with worse surgical outcomes, e.g. post-operative 
morbidity and mortality [2,3]. There is therefore a current interest 
in assessing the use of exercise prehabilitation in conjunction with 
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neoadjuvant cancer treatment to maintain and improve the levels of 
physical fitness for cancer patients prior to surgery. 
Regular physical activity during and after cancer treatment has 
also been shown to reduce the risk of recurrence and improve overall 
survival [5]. However, following a diagnosis of cancer, physical 
activity levels tend to decrease [6]. Exercise prehabilitation during 
neoadjuvant cancer treatment may therefore have an important role 
in preparing patients for the physiological stress of both neoadjuvant 
treatment and the surgical resection that follows. Prehabilitation 
with exercise can lead to skeletal muscle adaptations which 
improves oxygen uptake and increases mitochondrial content, both 
contributing to improved aerobic capacity, commonly accepted as 
the gold standard measure of physical fitness [7]. In colorectal cancer 
patients, an increase in physical activity levels by 50% following 
diagnosis, has been shown to decrease the risk of colorectal cancer-
specific as well as all-cause mortality [8]. Additionally, for women 
with breast cancer, it has been suggested that those who exercise for 
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thirty minutes or more, on five or more days a week, at moderate 
intensity, will have a lower risk of death [9]. 
There has been increasing interest in recent years in exercise-
oncology and the use of pre-operative prehabilitation. A systematic 
review in 2011, demonstrated that it was feasible and safe for 
patients with non-small cell lung cancer (NSCLC) to take part in 
exercise programmes both during and after their cancer treatment 
[10]. Currently, ongoing studies are predominantly focussed on 
prehabilitation before surgery as a single modality treatment, or 
rehabilitation after surgery prior to adjuvant treatment. Most 
studies are in patients with breast, prostate and rectal cancer and the 
applicability of these results to other tumour groups is uncertain. 
To date, no published systematic reviews have examined exercise 
prehabilitation in patients with gastrointestinal and thoracic cancer. 
Accordingly, the objective of this review was to systematically 
evaluate the methods and outcomes of all studies assessing exercise 
prehabilitation and neoadjuvant cancer treatment in patients with 
gastrointestinal and thoracic cancer.
Methods
Search strategy
A comprehensive, systematic search was performed on 3rd 
November 2016 and updated on 20th November 2016 and 28th 
November 2016 to identify all clinical studies that involved any form 
of exercise prehabilitation in addition to receiving neoadjuvant cancer 
treatment for patients with gastrointestinal and thoracic cancer. The 
following keywords and MeSH search terms were used: ‘exercise 
prehabilitation’, ‘cancer’, ‘surgery’, ‘treatment’, ‘neoadjuvant’, 
‘oesophageal’, ‘gastrointestinal’ and ‘thoracic’. Following an initial 
search for ‘exercise prehabilitation’ all further searches were carried 
out using Boolean terms and the above listed keywords. The following 
databases were used to obtain relevant studies for this review;
•	 Pubmed
•	 Ovid Medline (Journals@Ovid Full Text)
•	 Web of Science
•	 SCOPUS
•	 Cochrane Central Register of Controlled Trials (CENTRAL)
•	 ClinicalTrials.gov
The reference lists of all identified full-text articles were used to 
manually assess for any additional studies. References from previous 
review studies on exercise prehabilitation and cancer treatment were 
also assessed for inclusion. 
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Figure 1: PRISMA-style flow chart demonstrating the different phases of the systematic review [13].
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Study selection
For this new and emerging area of research, the inclusion criteria 
were broad and included randomised controlled trials (RCTs) and 
non-RCTs, pilot studies and all adult human trials. The studies needed 
to include an exercise prehabilitation intervention and any form of 
neoadjuvant cancer treatment in patients with gastrointestinal or 
thoracic cancer. All types of exercise prehabilitation interventions 
were included and this could take place before, during or after the 
neoadjuvant cancer treatment. The exclusion criteria for this review 
were trials that were not yet recruiting or where data was unpublished, 
studies where patients received adjuvant cancer treatment, studies 
with surgical intervention only and any studies with other cancers 
(non-gastrointestinal and non-thoracic). Case reports, published 
abstracts and previous reviews were also excluded.
Participants were therefore adults (>18years) with a 
gastrointestinal or thoracic cancer who were enrolled in any type of 
exercise prehabilitation intervention, where physical fitness was an 
outcome measure, who also had some form of neoadjuvant cancer 
treatment (chemotherapy or chemoradiotherapy).
Data extraction & quality assessment
Data extraction and the assessment of methodological quality 
were performed independently by two reviewers (RB and JZ) and the 
results were collated. The studies which met all the inclusion criteria 
were assessed for different study characteristics such as study design 
and length, participant’s characteristics, specific types of cancer, and 
the timing of the exercise prehabilitation intervention. The type of 
exercise prehabilitation intervention was also assessed including 
mode, duration, frequency, location and drop-out rates. The outcome 
variables that were assessed included cardiopulmonary exercise 
testing (CPET) derived variables, leg and arm muscle strength and 
functional exercise capacity, measured by maximum walking distance. 
Additional outcomes were safety and feasibility, health related quality 
of life measures and post-operative complications.
The Modified Downs and Black checklist [11] was used for 
the assessment of methodological quality of the included studies. 
This checklist can be used for assessing both randomised and non-
randomised studies [12] and it consists of 27 questions, with scores 
between 0 and 2, and a total score out of 28. The checklist assesses 
different aspects of quality including reporting, external validity, 
internal validity and bias, as well as assessing power. Higher quality 
studies are those with a higher score from the checklist. All scoring 
was done independently (RB and JZ) and then compared. Any 
inconsistencies were discussed and agreed.
Results 
A PRISMA style flow chart [13] is used to demonstrate the results 
of the initial systematic database search (Figure 1). A total of 502 
relevant abstracts were identified through database searching with an 
additional 6 abstracts being identified using reference lists from other 
First Author 
& Year of 
Publication
Study Design No. of Subjects Cancer Type Neoadjuvant Treatment
Exercise 
Prehabilitation 
Intervention
Outcomes Measurements
Heldens et al, 
2016
Single group 
prospective 
pilot study
13 (20)
Locally 
advanced 
resectable 
rectal cancer
NACRT (chemoradiotherap)
5.5 weeks
45 Gy in 25 fractions + boost 
dose
Oxaliplatin and Capecitabine
Individual 
supervised 
outpatient physical 
exercise training 
programme- 2 
sessions a week
1. Feasibility of 
physical exercise 
programme 
during NACRT
2. Physical 
Fitness 
(functional 
exercise 
capacity and 
muscle strength)
3. Quality of life 
and perception 
of fatigue
- Maximum walking 
distance- 6-minute 
walk test (6 MWT)
-Muscle strength- 
submaximal multiple 
repetition test (X-
RM)- leg press and 
chest press
West et al,
2015
Non-
randomised, 
parallel group, 
interventional 
prospective 
pilot study 
(blinded)
35 (39)
Locally 
advanced 
resectable 
rectal cancer
NACRT(chemoradiotherapy)
5 weeks
45 Gy in 25 fractions + boost 
dose
Capecitabine
6 week supervised 
in-hospital exercise 
training programme- 
3 sessions a week
1. Safety and 
feasibility 
of exercise 
intervention
2. Physical 
Fitness (oxygen 
uptake at lactate 
threshold)
3. Physical 
Activity (average 
number of steps)
- Changes in oxygen 
uptake at estimated 
lactate threshold 
(VO2LT)
-Changes in oxygen 
uptake at peak 
exercise (VO2peak)
-Changes in the 
number average 
number of steps
Huang et al,
2015
Retrospective 
cohort study 26 (32)
Oesophageal, 
gastric, 
colorectal and 
thoracic cancer
NACRT (chemoradiotherapy)
-No further details given
Individual exercise 
training programme 
with progressive 
aerobic and strength 
training exercises- 
3 to 5 sessions a 
week
1. Responders 
vs Non-
responders
2. Physical 
Fitness (oxygen 
uptake at 
anaerobic 
threshold)
3. Post-operative 
Complications
- Oxygen uptake 
(VO2) at anaerobic 
threshold (AT)
- Peak oxygen 
uptake (VO2peak)
- Oxygen uptake 
(VO2peak)/body 
surface area (BSA)
- Peak Work (Watts)
Table 1: Summary of Study Characteristics and Outcome Measures.
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relevant papers and reviews. Following the removal of any duplicates, 
all the relevant abstracts were screened by two independent reviewers 
(RB and JZ) and 323 abstracts were excluded. 18 full-text articles 
were then assessed for eligibility based on the inclusion and exclusion 
criteria outlined in the methods section. A further 15 articles were 
excluded as they did not meet all of these criteria. As demonstrated in 
the flow chart, following full screening and assessment for eligibility 
by two independent reviewers, three full text articles were identified 
for inclusion in this review. A full qualitative synthesis of these papers 
is provided however due to the small number of studies and the 
heterogeneity of outcome data being used, a meta-analysis has not 
been performed.
Study characteristics
The main characteristics of the three included studies are outlined 
in Table 1. There were no randomised controlled trials included 
in this review. The main aim of the three studies was to identify 
improvements in the physical fitness of cancer patients using exercise 
prehabilitation interventions in relation to neoadjuvant cancer 
treatments for those patients with gastrointestinal and/or thoracic 
cancers. Two of the included studies were prospective pilot studies 
[14,15], and one study was blinded at the point of data collection [15]. 
Heldens at el. carried out a single group study and West et al. used a 
parallel group study with an intervention (exercise prehabilitation) 
group and a control group [15]. The third study, by Huang et al. was 
a retrospective cohort study [16]. 
The number of study participants in the included studies 
ranged from 13 patients to 39 patients. Heldens et al. recruited 20 
participants, however five patients (25%) refused to take part and 
two more were excluded, leaving 13 (65%) patients enrolled in the 
exercise prehabilitation programme. Only nine of these patients 
(69.2%) completed the whole exercise prehabilitation programme 
[14]. West et al. recruited 39 subjects who were allocated into an 
exercise group (22 out of 22 subjects) and a control group (13 out of 
17 subjects), with four subjects (10.3%) dropping out prior to starting 
the exercise prehabilitation programme. Huang et al. referred 32 
consecutive patients to their study and of those who were eligible; 
six participants (18.7%) were excluded, leaving a total of 26 patients 
whose results were analysed. All three studies included both male and 
female patients with a greater percentage of male patients reported 
throughout. The mean age of participants was over 60 years in all 
three studies.
Two of the studies assessed exercise prehabilitation in the context 
of neoadjuvant treatment for locally advanced resectable rectal cancer 
[14,15]. Huang et al. included patients having three different types 
of surgery; oesophago-gastrectomy, complex colorectal surgery 
and thoracic cancer surgery. The two prospective studies included 
patients who underwent neoadjuvant treatment in the form of 
chemoradiotherapy prior to surgical resection. Of these two studies, 
one assessed exercise prehabilitation during this treatment [14] and 
the other assessed exercise prehabilitation following completion 
of the neoadjuvant treatment but prior to surgery [15]. Both rectal 
studies used a similar chemoradiotherapy regimen which lasted 5 to 
6 weeks with radiotherapy consisting of 45Gy in 25 fractions of 1.8Gy 
for 5 weeks with a boost dose given in the sixth week. Chemotherapy 
was given as oral capecitabine twice daily on radiotherapy days 
by West et al. whilst Heldens et al. administered oxaliplatin 
intravenously on day one in combination with oral capecitabine 
twice daily. The retrospective study also included patients undergoing 
chemoradiotherapy as a neoadjuvant treatment, with exercise 
prehabilitation being used following completion of treatment, 
however no further treatment details were provided [16].
Additionally, two of the studies assessed the safety and feasibility 
of implementing an exercise prehabilitation intervention in these 
patient groups [14,15]. Other outcomes that were assessed included 
physical activity measurements; health related quality of life, 
perception of fatigue and post-operative complications. 
First Author 
& Year of 
Publication
Study Design
Timing of Exercise 
Prehabilitation 
Intervention
Supervision 
and Location of 
Exercise Session
Exercise 
Session 
Duration & 
Frequency
Exercise 
Session 
Intensity
Type of 
Exercise
Duration of Exercise 
Prehabilitation
Attendance 
Rate
Heldens et al,
2016
Single group 
prospective pilot 
study
During NACRT- 
exercise 
prehabilitation 
commenced 
during first week 
of neoadjuvant 
treatment
Individual 
training sessions, 
supervised, in-
hospital
45-60 minutes
(2 x week)
Moderate 
Intensity
Endurance 
(treadmill and 
ergometer) 
and resistance 
exercises
9-17 weeks
95.7%
West et al, 2015
Non-randomised, 
parallel group, 
interventional 
prospective pilot 
study (blinded)
Post-NACRT- 
exercise 
prehabilitation 
commenced 
immediately 
following completion 
of neoadjuvant 
treatment
Paired training 
sessions, 
supervised, in-
hospital
40 minutes
(3 x week)
Moderate 
to Severe 
Intensity
Interval training 
(ergometer)
6 weeks 96%
Huang et al, 
2015
Retrospective 
cohort study
Post- NACRT- 
exercise 
prehabilitation 
commenced 
following completion 
of neoadjuvant 
treatment
Individual 
training sessions, 
supervised and 
unsupervised, 
at home (50%), 
in-hospital 
(23%) and in the 
community (27%)
20-45 minutes
(3-5 x week)
Severe 
Intensity
Progressive 
interval training 
(aerobic) and 
strength training 
exercises
26- 461 days 
(median 74 days)
77% (completed 
> 80% of 
the exercise 
programme)
Table 2: Summary of Exercise Prehabilitation Intervention Characteristics.
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Exercise prehabilitation characteristics
All three studies included an exercise prehabilitation intervention 
alongside a form of neoadjuvant cancer treatment prior to 
plan surgical resection. The main characteristics of the exercise 
prehabilitation interventions used in the studies are summarised in 
Table 2. Heldens et al. was the only study which assessed the use of an 
exercise prehabilitation intervention during neoadjuvant treatment. 
Both of the other studies assessed the use of an exercise prehabilitation 
intervention following completion of the neoadjuvant treatment but 
prior to planned surgical resection [15,16]. 
The location and supervision of the exercise prehabilitation 
intervention was varied across the studies. Although all three 
studies used an individualised training programme, West et al. 
allowed subjects to exercise in pairs to encourage camaraderie and 
improve adherence [15]. In the other studies, participants exercised 
alone, however they were supervised in hospital by trained physical 
therapists in the single group study by Heldens et al. [14]. Huang et 
al. allowed subjects to exercise individually at home (50%), in the 
community (27%) or supervised in the hospital (23%). 
The exercise prehabilitation intervention sessions lasted between 
20 and 60 minutes across the three studies and were performed 
between two and five times a week [14-16]. The intensity of the 
exercise intervention session was also varied across the three studies. 
Huang et al. used a severe intensity exercise training programme 
that was progressive over its duration and was based on subjects 
working to 60-80% of their maximum heart rate measured at peak 
oxygen consumption (VO2peak). West et al. used an exercise training 
programme which alternated between moderate and severe intensity, 
also defined using maximum heart rate (50-80%) and peak oxygen 
consumption (VO2peak). A moderate intensity exercise training 
programme (50-60% maximum heart rate; estimated using the 
formula: 220-age) was used by Heldens et al. [14]. 
Different types of exercise were used for the exercise prehabilitation 
interventions. Interval and endurance training using an ergometer 
was used in all three studies [14-16]. In addition, Heldens et al. used 
three resistance exercises (leg press, chest press and lateral pull down) 
as part of their exercise prehabilitation programme. Huang et al. 
also included strength training exercises but no further information 
regarding these exercises was provided [16]. 
The duration of the exercise prehabilitation programmes was 
diverse (26-461 days). In two of the studies it was partly dependent 
on the length of time between completing neoadjuvant treatment and 
the planned surgical resection [14,16]. West et al. used a structured 
six-week exercise training programme following completion of 
neoadjuvant treatment. Adherence to the exercise prehabilitation 
programme was similar in the two prospective studies (>95% 
attendance rate) [14,15]. In contrast, adherence was much lower in 
the retrospective study where 77% in the ‘responder’ group and as low 
as 39% in the ‘non-responder’ group was noted [16]. 
Exercise prehabilitation measurements and outcomes 
Measurements: All three of the included studies used physical 
fitness as a primary outcome measure. The measurements for 
physical fitness were performed differently in each study. Heldens 
et al. used functional exercise capacity, measured by a six-minute 
walk test (6MWT), with maximum walking distance as a primary 
outcome measure. Muscle strength was also measured using the sub 
maximal multiple-repetition (X-RM) test procedure for two different 
resistance exercises: leg press and chest press (14). All measurements 
were taken at baseline (B), after five weeks of training (T1), after ten 
weeks of training (T2) and eight weeks post-operatively (T3). West 
et al. measured physical fitness using cardiopulmonary exercise 
testing (CPET) derived variables and also assessed physical activity 
using a biaxial accelerometer measuring average step count over a 
72-hour period. The CPET-derived variables assessed were: changes 
in oxygen uptake at estimated lactate threshold (VO2LT), changes in 
oxygen uptake at peak exercise (VO2peak) and changes in the number 
average number of steps [15]. Measurements were taken two weeks 
before NACRT (baseline), immediately post-NACRT (week 0) and 
then at weeks 3, 6, 9, and 14 before their surgery during week 15. Both 
these studies additionally assessed the safety and feasibility of using 
the exercise prehabilitation programme. Huang et al. also measured 
physical fitness using CPET-derived gas exchange variables. They 
included oxygen uptake (VO2) at anaerobic threshold (AT), peak 
oxygen uptake (VO2peak), and oxygen uptake (VO2peak)/body surface 
area (BSA) [16]. In this study subjects were also defined as ‘responders’ 
to the exercise prehabilitation programme if they had >10% 
improvement in AT, based on 10% being reported as the coefficient 
of variation for repeated CPET assessment [17]. ‘Non-responders’ 
were those patients who had less than 10% increase in AT following 
the exercise prehabilitation programme [16]. CPET measurements 
were performed at baseline, prior to the exercise prehabilitation 
programme (CPX1) and following the exercise prehabilitation 
programme, prior to surgery (CPX2). For those patients who had 
neoadjuvant chemotherapy (11 of 26 subjects), a third CPET test was 
performed following the completion of treatment. 
Additional secondary outcomes included the assessment of 
health-related quality of life and patient perception of fatigue 
using structured self-reported questionnaires [14]. Post-operative 
complications were also assessed to see if the exercise prehabilitation 
programme was associated with improved post-operative outcomes. 
This was performed using the Clavien-Dindo Classification, where a 
major post-operative complication was defined by a score of >3 which 
the authors felt was more likely to represent impaired cardiopulmonary 
reserve rather than a surgical or technical complication [16]. 
Outcomes: All the included studies demonstrated some 
improvement in the main primary outcome, physical fitness, 
following the use of an exercise prehabilitation programme. In 
the Heldens et al. study functional exercise capacity as measured 
by walking distance improved across the duration of the exercise 
prehabilitation programme but none of the observed differences were 
statistically significant [14]. The biggest change was observed when 
walking distance at T2 was compared to walking distance at baseline, 
where seven of eight (87.5%) patients walked a longer distance (mean 
+/- SD distance 555.6 +/- 101.7m vs 509.6 +/- 124.5m, respectively; 
P=0.075). However, some observed changes in leg and arm muscle 
strength were shown to be statistically significant [14]. Although both 
arm and leg muscle strength improved, no statistically significant 
results were observed between measurements at baseline and T1 or 
between T1 and T2. At T2 compared to baseline, eight out of eight 
(100%) patients had improved their leg muscle strength (mean +/- 
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SD strength of 144.8 +/- 45.6kg vs 104.0 +/- 32.3kg, respectively; P 
<0.001). This represented a mean improvement in leg strength of 
39.2%(14).Also at T2 compared to baseline, eight out of eight patients 
(100%) had improved their arm muscle strength (mean +/- SD 
strength of 48.7 +/- 13.8kg vs 36.1 +/- 11.0kg respectively; P= 0.002, 
representing a mean improvement in arm muscle strength of 34.9%) 
[14].
West et al. used a CPET measurement immediately following 
completion of neoadjuvant chemoradiotherapy and demonstrated a 
significant reduction in VO2LT (-1.91ml kg-1 min-1; 95% CI -1.27 to 
-2.55; P< 0.0001) and VO2peak (-2.52ml kg-1 min-1; 95% CI -1.33 to 
-3.71; P<0.0001) [15]. During the intervention period (weeks 0-6), 
the exercise group showed a significant improvement in both primary 
endpoints. VO2LT improved in the exercise group by +2.12mlkg-1min-1 
(95% CI +1.34-2.90; P< 0.0001), whilst in the control group it did not 
(-0.65ml kg-1min-1, 95% CI -1.66 to +0.37; P=0.204). VO2peak results 
were similar with improvement in the exercise group by +2.65 ml 
kg-1min-1 (95% CI +1.19-4.10; P= 0.0005), whereas the control group 
reduced by -1.25 ml kg-1min-1 (95% CI -3.14 to +0.64; P=0.19). All 
these analyses were adjusted for potential confounders which had a 
negligible effect [15]. A significant difference was also observed in the 
average number of steps for the exercise and control groups between 
week 0 and week 6 (P< 0.0001 and P=0.003) as well as between 
baseline and week 0 for all subjects (P=0.0004) [15]. 
In the retrospective cohort study of Huang et el., a significant 
overall improvement in functional capacity was observed across three 
of the measured CPET-derived domains: AT increased 9% from 10.4 
to 11.6 ml kg-1min-1; P=0.046; VO2peak increased 9% from 16.0 to 17.7 
ml kg-1min-1; P=0.002; and VO2peak/BSA increased 10% from 658 to 
726 ml min-1m-2; P=0.004 (16). Half of the study subjects (50%) were 
defined as ‘responders’ to their individual exercise prehabilitation 
programme. For all patients, there was a median improvement 
between CPX1 and CPX2 in peak work performed of 14% from 100 
to 113 W; P=0.0018. ‘Responders’ showed an increase in peak work 
of 19% (94-115 W; P=0.024) but this improvement was not observed 
in the ‘non-responder’ group(16). In a comparison of baseline 
characteristics between the ‘responder’ and ‘non-responder’ groups, 
no statistically significant differences were observed. For those 
patients who underwent neoadjuvant treatment, functional capacity 
demonstrated an insignificant decline following the completion of 
treatment (AT decreased 5.1%, IQR -5.9% to 16.1%, from 10.4 +/- 2.8 
to 9.7 +/- 1.3mlkg-1min-1; P=0.23 and VO2peak decreased 6.8%, IQR 
-3.6% to 17.2%, from 15.7 +/- 4.6 to 14.7 +/- 3.0mlkg-1min-1; P=0.24). 
However, a significant improvement was observed between the post-
neoadjuvant treatment CPET test and the final pre-surgical CPET 
(CPX2) test (AT increased 13.6%, IQR 4.6% to 22.7%, from 9.7 +/- 1.3 
to 11.4 +/- 1.6mlkg-1min-1; P<0.001 and VO2peak increased 11.2 %, IQR 
2.7% to 19.8%, from 14.7 +/- 3.0 to 16.5 +/- 3.6mlkg-1min-1; P=0.004) 
[16]. 
Additionally, ‘non-responders’ were observed to trend towards 
suffering more major post-operative complications (Clavien-Dindo 
classification >3= 30.8%, ‘non-responders’ vs 0% in ‘responders’; 
P=0.096). ‘Non-responders’ were also more likely to have completed 
their exercise prehabilitation programme unsupervised, at home 
(69% vs. 31%, ‘responder’ vs. ‘non-responder’ respectively, P=0.03) 
[16]. Heldens et al. reported the exercise prehabilitation programme 
to be both safe and feasible based on adherence rates (95.7%) and a 
lack of adverse events occurring during the intervention [14]. West 
et al. also concluded that the exercise prehabilitation used was both 
safe and feasible, with good overall adherence (96%) and no adverse 
events reported [15]. No significant differences were observed using 
the multi-dimensional fatigue index (MFI) or the short form 36 
health survey (36) used to assess perception of fatigue and health 
related quality of life respectively [14]. 
Quality assessment: The methodological quality of the three 
included studies was assessed using the Modified Downs and Black 
Checklist [11]. Each study was independently reviewed (RB and 
JZ). The highest methodological score was 21 out of 28 and this was 
observed in the prospective pilot study by Heldens et al [14]. The 
lowest methodological score was 17 out of 28 and this was observed 
in the retrospective cohort study by Huang et al [16]. West et al. had 
a methodological score of 20 out of 28 [15].
Discussion
Overview & quality of included studies
One of the difficulties in assessing the available literature on 
exercise prehabilitation remains the heterogeneity of study subjects, 
caused by variations in cancer treatment algorithms between tumour 
groups, and notable differences in the magnitude of the surgical insult. 
This is the first systematic review, focussing specifically on patients 
with gastrointestinal and thoracic cancers, to assess the use of exercise 
prehabilitation during neo-adjuvant cancer treatment. The intention 
was to assess the benefit of exercise in a relatively homogenous group 
of patients but the paucity of studies meeting the inclusion criteria 
highlighted the novelty of this emerging area of research.
All of the included studies demonstrated some improvement 
in the main primary outcome of physical fitness, measured using 
either CPET-derived variables or maximum walking distance and 
muscle strength. In addition, all three studies demonstrated that an 
exercise prehabilitation programme in the setting of neoadjuvant 
cancer treatment for patients with gastrointestinal and thoracic 
cancer was both feasible and safe. The quality of the included studies 
was variable. No randomised controlled trials were identified 
that could be included in this review. There were two prospective 
pilot studies and one retrospective cohort study [14-16]. Only one 
study, by West et al had a control group and also used blinding at 
the point of data collection [15]. The number of subjects in each 
of the three studies was small (13 to 39 participants). Two of the 
three included studies involved patients with rectal cancer and the 
third study involved patients undergoing oesophago-gastrectomy, 
complex colorectal surgery and thoracic cancer surgery. Adherence 
to the exercise prehabilitation programmes was good, although the 
adherence rates were higher when the programme was supervised 
within a hospital setting. Only one of the studies assessed the use of 
exercise prehabilitation during neoadjuvant cancer treatment. The 
two prospective studies assessed exercise following the completion of 
neoadjuvant cancer treatment but prior to surgical resection [14,15]. 
Given the well-established deleterious effects of these treatments on 
physical fitness and outcomes following surgery, this highlights a 
specific area where further studies are required [18-20].
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Type of measurements and outcomes
The primary outcome in all three studies was to assess changes 
in physical fitness through the implementation of an exercise 
prehabilitation programme either during or after neoadjuvant cancer 
treatment. However, physical fitness was measured in different ways 
in each of the different studies. In two of the studies, CPET-derived 
variables were used. Unlike testing individual organ systems, CPET 
testing provides an objective global assessment of a patient’s fitness 
[21]. CPET is commonly used for evaluating perioperative risk for 
many different types of surgery including major intra-abdominal 
surgery [22,23]. In patients having major elective surgery, a lower 
anaerobic threshold is associated with an elevated mortality post-
surgery [24]. Furthermore, many studies have shown a consistent 
relationship between physical fitness, defined by CPET-derived 
variables, and postoperative outcomes [25,26]. The use of CPET in 
the perioperative setting has significantly increased over the past 
two decades and its use for assessing physical fitness in patients 
participating in an exercise prehabilitation programme was therefore 
justified. Two of the included studies used CPET-derived variables 
to measure their primary outcome [15,16]. The only study which 
assessed exercise prehabilitation during neoadjuvant treatment 
did not include any CPET measurements [14]. Whilst it is unclear 
why CPET-derived variables were not measured in this study, there 
is evidence to support the use of muscle strength as a measure of 
physical fitness [27].
High adherence rates and no adverse events following exercise 
programmes would support the conclusion that such interventions are 
both feasible and safe. Whether there are truly ‘responders’ and ‘non-
responders’ to exercise programmes as reported by Huang remains 
uncertain, particularly given the discrepancies in the levels of patient 
supervision. Undoubtedly there will be variations amongst patients 
in terms of co-morbidities, baseline physical fitness and compliance 
that will affect the overall impact of an exercise programme, but this 
might be taken to support a more individually tailored and structured 
programme that incorporates these factors. Post-operative outcomes, 
health-related quality of life and perception of fatigue were included 
in these studies but all were considered as secondary outcomes.
There has been increasing evidence to suggest that exercise 
prehabilitation following neoadjuvant cancer therapy is safe and 
feasible in numerous different cancer types, predominantly in breast 
cancer [28-30] and rectal cancer [15], however this finding is new 
with regard to gastrointestinal and thoracic cancer as shown in this 
review. 
Limitations
The limitations of this review centre on the paucity and low 
quality of the eligible clinical studies which also exhibited significant 
heterogeneity. There were no randomised controlled trials identified 
and the numbers of subjects involved were small. Although there was 
some overlap between the studies, a meta-analysis was not performed.
Conclusions
There is some preliminary evidence supporting the use of exercise 
prehabilitation in patients undergoing neo-adjuvant treatment 
followed by surgery for cancer. However, whilst inherently logical, 
there is a conspicuous lack of robust data to support exercise 
programmes in a way that might help guide the optimal timing, 
duration, location and frequency of these interventions. In addition, 
the positive impact of exercise may be broad, including, but not 
limited to, physical fitness, mood, activity levels, quality of life, post-
operative morbidity and mortality and long-term cancer survival. 
Future studies to define these optimal outcome measures and develop 
guidelines for the use of exercise prehabilitation in cancer patients 
would be beneficial. 
References
1. Carli F, Charlebois P, Stein B, Feldman L, Zavorsky G, Kim DJ, et al. 
Randomized clinical trial of prehabilitation in colorectal surgery. Br J Surg. 
England; 2010; 97: 1187–1197. 
2. West MA, Loughney L, Barben CP, Sripadam R, Kemp GJ, Grocott MPW, 
et al. The effects of neoadjuvant chemoradiotherapy on physical fitness 
and morbidity in rectal cancer surgery patients. Eur J Surg Oncol. 2014; 40: 
1421–1428. 
3. Jack S, West MA, Raw D, Marwood S, Ambler G, Cope TM, et al. The effect 
of neoadjuvant chemotherapy on physical fitness and survival in patients 
undergoing oesophagogastric cancer surgery. Eur J Surg Oncol. 2014; 40: 
1313–1320. 
4. Moros MT, Ruidiaz M, Caballero A, Serrano E, Martínez V, Tres A. Effects 
of an exercise training program on the quality of life of women with breast 
cancer on chemotherapy. Rev Med Chil. 2010; 138: 715–722. 
5. Thomas R, Holm M, Al-Adhami A. Physical activity after cancer: an evidence 
review of the international literature. Br J Med Pract. 2014; 7: a708. 
6. Adamsen L, Quist M, Andersen C, Møller T, Herrstedt J, Kronborg D, et al. 
Effect of a multimodal high intensity exercise intervention in cancer patients 
undergoing chemotherapy: randomised controlled trial. BMJ. 2009; 339: 
b3410. 
7. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise 
and their metabolic consequences. J Appl Physiol. 1984; 56: 831–838. 
8. Meyerhardt J a, Giovannucci EL, Holmes MD, Chan AT, Chan J a, Colditz G 
a, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin 
Oncol [Internet]. 2006; 24: 3527–3534. 
9. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical 
activity and survival after breast cancer diagnosis. JAMA. 2005; 293: 2479–
2486. 
10. Granger CL, McDonald CF, Berney S, Chao C, Denehy L. Exercise 
intervention to improve exercise capacity and health related quality of life for 
patients with Non-small cell lung cancer: A systematic review. Lung Cancer. 
2011; 72: 139–153. 
11. Trac MH, McArthur E, Jandoc R, Dixon SN, Nash DM, Hackam DG, et al. 
Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. 
CMAJ. 2016; 188: e120–129. 
12. Downs SH, Black N. The feasibility of creating a checklist for the assessment 
of the methodological quality both of randomised and non-randomised 
studies of health care interventions. J Epidemiol Community Health. 1998; 
52: 377–384. 
13. Moher D, Liberati A, Tetzlaff J AD. PRISMA 2009 Flow Diagram. The PRISMA 
statement. 2009. p. 1000097. 
14. Heldens AFJM, Bongers BC, de Vos-Geelen J, van Meeteren NLU, Lenssen 
AF. Feasibility and preliminary effectiveness of a physical exercise training 
program during neoadjuvant chemoradiotherapy in individual patients with 
rectal cancer prior to major elective surgery. Eur J Surg Oncol. 2016; 1–9. 
15. West MA, Loughney L, Lythgoe D, Barben CP, Sripadam R, Kemp GJ, et 
al. Effect of prehabilitation on objectively measured physical fitness after 
neoadjuvant treatment in preoperative rectal cancer patients: a blinded 
interventional pilot study. Br J Anaesth. England; 2015; 114: 244–251. 
16. Huang GH, Ismail H, Murnane A, Kim P, Riedel B. Structured exercise 
program prior to major cancer surgery improves cardiopulmonary fitness: a 
Gastrointest Cancer Res Ther 2(1): id1014 (2017)  - Page - 08
Bott RK Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
retrospective cohort study. Support Care Cancer. 2016; 24: 2277–2285. 
17. Kothmann E, Danjoux G, Owen SJ, Parry A, Turley AJ, Batterham AM. 
Reliability of the anaerobic threshold in cardiopulmonary exercise testing of 
patients with abdominal aortic aneurysms. In: Anaesthesia. 2009. p. 9–13. 
18. Awad S, Tan BH, Cui H, Bhalla A, Fearon KCH, Parsons SL, et al. Marked 
changes in body composition following neoadjuvant chemotherapy for 
oesophagogastric cancer. Clin Nutr. 2012; 31: 74–77. 
19. Tan BHL, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, et 
al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant 
chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015; 41: 
333–338. 
20. Sahai SK. Perioperative assessment of the cancer patient. Best Pract Res 
Clin Anaesthesiol. Elsevier Ltd; 2013; 27: 465–480. 
21. Levett DZH, Grocott MPW. Cardiopulmonary exercise testing, prehabilitation, 
and Enhanced Recovery After Surgery (ERAS) [Test d’effort cardiopulmonaire, 
préadaptation et récupération rapide après la chirurgie (RRAC)]. Can J 
Anesth. Springer New York LLC. 2015; 62: 131–142. 
22. Wilson RJT, Davies S, Yates D, Redman J, Stone M. Impaired functional 
capacity is associated with all-cause mortality after major elective intra-
abdominal surgery. Br J Anaesth. 2010; 105: 297–303. 
23. Hennis PJ, Meale PM, Hurst RA, O’Doherty AF, Otto J, Kuper M, et al. 
Cardiopulmonary exercise testing predicts postoperative outcome in patients 
undergoing gastric bypass surgery. Br J Anaesth. 2012; 109: 566–571. 
24. Older P, Smith R, Courtney P, Hone R. Preoperative evaluation of cardiac 
failure and ischemia in elderly patients by cardiopulmonary exercise testing. 
Chest. 1993; 104: 701–704. 
25. Smith TB, Stonell C, Purkayastha S, Paraskevas P. Cardiopulmonary 
exercise testing as a risk assessment method in non cardio-pulmonary 
surgery: a systematic review. Anaesthesia. 2009; 64: 883–893. 
26. West M, Jack S, Grocott MPW. Perioperative cardiopulmonary exercise 
testing in the elderly. Best Pract Res Clin Anaesthesiol. 2011; 25: 427–437. 
27. Strasser B, Steindorf K, Wiskemann J, Ulrich CM. Impact of resistance 
training in cancer survivors: A meta-analysis. Med Sci Sports Exerc. 2013; 
45: 2080–2090. 
28. Hornsby WE, Douglas PS, West MJ, Kenjale A a, Lane AR, Schwitzer ER, et 
al. Safety and efficacy of aerobic training in operable breast cancer patients 
receiving neoadjuvant chemotherapy: a phase II randomized trial. Acta 
Oncol. 2014; 53: 65–74. 
29. Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, et al. 
Modulation of circulating angiogenic factors and tumor biology by aerobic 
training in breast cancer patients receiving neoadjuvant chemotherapy. 
Cancer Prev Res. 2013; 6: 925–937. 
30. Rao R, Cruz V, Peng Y, Harker-Murray A, Haley BB, Zhao H, et al. Bootcamp 
during neoadjuvant chemotherapy for breast cancer: A randomized pilot trial. 
Breast Cancer Basic Clin Res. 2012; 6: 39–46.
Citation: Bott RK, Zylstra J, Whyte G and Davies AR. Exercise Prehabilitation during Neoadjuvant Cancer 
Treatment in Patients with Gastrointestinal and Thoracic Cancer: A Systematic Review. Gastrointest Cancer 
Res Ther. 2017; 2(1): 1014.
Gastrointest Cancer Res Ther - Volume 2 Issue 1 - 2017
Submit your Manuscript | www.austinpublishinggroup.com 
Bott et al. © All rights are reserved
